Rimantadine
Mechanism :
Exerts its inhibitory effect on three antigenic subtypes of influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle, possibly inhibiting the uncoating process.
Indication :
- Influenza A virus, prophylaxis and treatment
Contraindications :
Hypersensitivity to rimantadine, other adamantanes or any component of the formulation.
Dosing :
Influenza A virus, prophylaxis:
>1 year and <40 kg:
5 mg/kg/day PO in 1 to 2 divided doses for 7 days after last known exposure. Maximum: 150 mg/day upto 9 years of age and 200 mg/day in ≥10 years.
≥40 kg:
100 mg PO twice daily for 7 days after last known exposure.
Influenza A virus, treatment:
>17 years:
100 mg PO twice daily for 5 to 7 days.
Adverse Effect :
Insomnia, lack of concentration, dizziness, nervousness, nausea, anorexia, vomiting, xerostomia, weakness.
Interaction :
Antiviral Agents: May diminish the therapeutic effect of Influenza Virus Vaccine.
Hepatic Dose :
No specific pediatric dose adjustment is given, however recommendations are based on experience with adults.
Mild to moderate hepatic impairment: No dosage adjustments are recommended.
Severe hepatic impairment: Daily dose should be halved.